Cerebrovascular EveNts in Patients Undergoing TranscathetER Aortic Valve Implantation With Balloon-expandable Valves Versus Self-expandable Valves.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Aortic Valve Stenosis
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Enrollment
- 12000
- Locations
- 1
- Primary Endpoint
- Stroke
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The aim of this collaborative analysis is to evaluate stroke rates and mortality in patients undergoing TAVI with the self-expandable MCV prosthesis compared to the balloon-expandable ES valve. In the absence of large randomized controlled trials, we will conduct a large collaborative patient-pooled meta-analysis on 30-day stroke and mortality in patients undergoing primary transfemoral TAVI with either MCV or ES valve.
Detailed Description
The main aim of this patient-pooled analyses is to compare stroke rates and mortality in patients undergoing TAVI with the self-expandable MCV prosthesis compared to the balloon-expandable ES valve. However, this collaboration may also be used to compare various outcomes. Studies were included if they complied with the following requirements: original prospective studies, including patients with aortic valve stenosis treated with transfemoral TAVI of native valves and reporting of 30 day stroke outcomes according to VARC criteria or other specified corresponding criteria . Moreover, to be included studies had to report both the use of self-expandable MCV prosthesis and the balloon-expandable ES valve in more than 50 patients in each arm to ensure experience in use of the valves. Studies were excluded if they only addressed patients undergoing valve-in-valve and re-do procedures or bicuspid valves or included the same study population. Principal Investigators of these studies were approached for collaboration.
Investigators
Jan J. Piek, MD, PhD
Professor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Eligibility Criteria
Inclusion Criteria
- •patients undergoing transfemoral transcatheter aortic valve procedures
Exclusion Criteria
- •valve-in-valve procedures, other acces routes than transfemoral
Outcomes
Primary Outcomes
Stroke
Time Frame: 30 days
Stroke during the first month after TAVI
Mortality
Time Frame: 30 days
Death during the first month after TAVI
Secondary Outcomes
- New onset atrial fibrillation(30 days)
- Pacemaker implantation(30 days)
- Myocardial infarction(30 days)
- Bleeding(30 days)